Repligen (NASDAQ:RGEN) Upgraded to Buy by Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft upgraded shares of Repligen (NASDAQ:RGEN) from a hold rating to a buy rating in a report published on Wednesday morning, Marketbeat reports. Deutsche Bank Aktiengesellschaft currently has $155.00 price objective on the biotechnology company’s stock, down from their previous price objective of $180.00.

A number of other analysts have also commented on the company. Guggenheim initiated coverage on Repligen in a research note on Tuesday, June 18th. They set a neutral rating on the stock. JPMorgan Chase & Co. reduced their target price on shares of Repligen from $230.00 to $200.00 and set an overweight rating on the stock in a report on Thursday, May 2nd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of Moderate Buy and a consensus price target of $193.00.

Repligen Price Performance

Shares of NASDAQ RGEN opened at $127.00 on Wednesday. The company has a current ratio of 6.35, a quick ratio of 5.24 and a debt-to-equity ratio of 0.26. The stock has a market cap of $7.10 billion, a price-to-earnings ratio of 508.02, a PEG ratio of 4.11 and a beta of 1.04. The company’s 50-day moving average price is $152.94 and its 200 day moving average price is $174.43. Repligen has a 52 week low of $110.45 and a 52 week high of $211.13.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.01). Repligen had a return on equity of 3.95% and a net margin of 2.44%. The business had revenue of $151.31 million for the quarter, compared to analysts’ expectations of $150.06 million. During the same period last year, the business earned $0.64 earnings per share. The company’s revenue for the quarter was down 17.1% on a year-over-year basis. As a group, research analysts forecast that Repligen will post 1.46 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Anthony Hunt sold 20,072 shares of the business’s stock in a transaction on Tuesday, May 21st. The shares were sold at an average price of $168.26, for a total transaction of $3,377,314.72. Following the completion of the sale, the chief executive officer now directly owns 163,177 shares of the company’s stock, valued at approximately $27,456,162.02. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other Repligen news, Director Martin D. Madaus purchased 1,615 shares of the business’s stock in a transaction that occurred on Friday, June 14th. The shares were purchased at an average price of $124.94 per share, for a total transaction of $201,778.10. Following the completion of the acquisition, the director now owns 4,613 shares of the company’s stock, valued at approximately $576,348.22. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Anthony Hunt sold 20,072 shares of the business’s stock in a transaction that occurred on Tuesday, May 21st. The stock was sold at an average price of $168.26, for a total transaction of $3,377,314.72. Following the sale, the chief executive officer now owns 163,177 shares of the company’s stock, valued at $27,456,162.02. The disclosure for this sale can be found here. 1.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Repligen

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Retirement Systems of Alabama lifted its stake in shares of Repligen by 0.4% during the fourth quarter. Retirement Systems of Alabama now owns 65,032 shares of the biotechnology company’s stock worth $11,693,000 after purchasing an additional 288 shares in the last quarter. Evoke Wealth LLC acquired a new stake in Repligen in the fourth quarter valued at approximately $1,955,000. International Assets Investment Management LLC raised its stake in shares of Repligen by 18,449.1% during the fourth quarter. International Assets Investment Management LLC now owns 58,615 shares of the biotechnology company’s stock valued at $10,539,000 after purchasing an additional 58,299 shares during the period. Congress Asset Management Co. MA lifted its position in shares of Repligen by 14.6% during the first quarter. Congress Asset Management Co. MA now owns 88,013 shares of the biotechnology company’s stock worth $16,187,000 after purchasing an additional 11,213 shares in the last quarter. Finally, American Century Companies Inc. boosted its stake in shares of Repligen by 97.5% in the third quarter. American Century Companies Inc. now owns 217,900 shares of the biotechnology company’s stock valued at $34,648,000 after purchasing an additional 107,570 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.